Teleflex Incorporated TFX
The next Teleflex Incorporated dividend went ex 10 days ago for 34c and will be paid in 23 days.
The previous Teleflex Incorporated dividend was 34c and it went ex 3 months ago and it was paid 2 months ago.
There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 8.2.
|Summary||Previous dividend||Next dividend|
|Declaration date||24 Feb 2022 (Thu)||02 May 2022 (Mon)|
|Ex-div date||04 Mar 2022 (Fri)||13 May 2022 (Fri)|
|Pay date||15 Mar 2022 (Tue)||15 Jun 2022 (Wed)|
Enter the number of Teleflex Incorporated shares you hold and we'll calculate your dividend payments:
Sign up for Teleflex Incorporated and we'll email you the dividend information when they declare.
Add Teleflex Incorporated to receive free notifications when they declare their dividends.
Your account is set up to receive Teleflex Incorporated notifications.
|Status||Type||Decl. date||Ex-div date||Pay date||Decl. Currency||Forecast amount||Decl. amount||Accuracy|
|Forecast||Quarterly||25 Feb 2027||26 Feb 2027||15 Mar 2027||USD||Sign up||—|
|Forecast||Quarterly||29 Oct 2026||12 Nov 2026||15 Dec 2026||USD||Sign up||—|
|Forecast||Quarterly||30 Jul 2026||13 Aug 2026||15 Sep 2026||USD||Sign up||—|
|Forecast||Quarterly||04 May 2026||14 May 2026||15 Jun 2026||USD||Sign up||—|
|Forecast||Quarterly||19 Feb 2026||27 Feb 2026||16 Mar 2026||USD||Sign up||—|
|Forecast||Quarterly||30 Oct 2025||13 Nov 2025||15 Dec 2025||USD||Sign up||—|
|Forecast||Quarterly||31 Jul 2025||14 Aug 2025||15 Sep 2025||USD||Sign up||—|
|Forecast||Quarterly||05 May 2025||14 May 2025||16 Jun 2025||USD||Sign up||—|
|Forecast||Quarterly||20 Feb 2025||28 Feb 2025||17 Mar 2025||USD||Sign up||—|
|Forecast||Quarterly||31 Oct 2024||14 Nov 2024||16 Dec 2024||USD||Sign up||—|
|Forecast||Quarterly||01 Aug 2024||14 Aug 2024||16 Sep 2024||USD||Sign up||—|
|Forecast||Quarterly||06 May 2024||14 May 2024||14 Jun 2024||USD||Sign up||—|
|Forecast||Quarterly||22 Feb 2024||01 Mar 2024||15 Mar 2024||USD||Sign up||—|
|Forecast||Quarterly||02 Nov 2023||14 Nov 2023||15 Dec 2023||USD||Sign up||—|
|Forecast||Quarterly||03 Aug 2023||14 Aug 2023||15 Sep 2023||USD||Sign up||—|
|Forecast||Quarterly||08 May 2023||12 May 2023||15 Jun 2023||USD||Sign up||—|
|Forecast||Quarterly||23 Feb 2023||03 Mar 2023||15 Mar 2023||USD||Sign up||—|
|Forecast||Quarterly||27 Oct 2022||14 Nov 2022||15 Dec 2022||USD||Sign up||—|
|Forecast||Quarterly||28 Jul 2022||12 Aug 2022||15 Sep 2022||USD||Sign up||—|
|Declared||Quarterly||02 May 2022||13 May 2022||15 Jun 2022||USD||34c||34c||😄|
|Paid||Quarterly||24 Feb 2022||04 Mar 2022||15 Mar 2022||USD||34c||34c||😄|
|Paid||Quarterly||28 Oct 2021||12 Nov 2021||15 Dec 2021||USD||34c||34c||😄|
|Paid||Quarterly||29 Jul 2021||13 Aug 2021||15 Sep 2021||USD||34c||34c||😄|
|Paid||Quarterly||03 May 2021||13 May 2021||15 Jun 2021||USD||34c||34c||😄|
|Paid||Quarterly||31 Dec 2020||04 Mar 2021||15 Mar 2021||USD||34c||34c||😄|
|Paid||Quarterly||29 Oct 2020||12 Nov 2020||15 Dec 2020||USD||34c||34c||😄|
|Paid||Quarterly||30 Jul 2020||13 Aug 2020||15 Sep 2020||USD||34c||34c||😄|
|Paid||Quarterly||04 May 2020||14 May 2020||15 Jun 2020||USD||34c||34c||😄|
|Paid||Quarterly||20 Feb 2020||28 Feb 2020||16 Mar 2020||USD||34c||34c||😄|
|Paid||Quarterly||31 Oct 2019||14 Nov 2019||16 Dec 2019||USD||34c||34c||😄|
|Paid||Quarterly||01 Aug 2019||14 Aug 2019||16 Sep 2019||USD||—||34c|
|Paid||Quarterly||06 May 2019||14 May 2019||14 Jun 2019||USD||—||34c|
|Paid||Quarterly||21 Feb 2019||28 Feb 2019||15 Mar 2019||USD||—||34c|
|Paid||Quarterly||01 Nov 2018||14 Nov 2018||14 Dec 2018||USD||—||34c|
|Paid||Quarterly||02 Aug 2018||14 Aug 2018||14 Sep 2018||USD||—||34c|
|Paid||Quarterly||07 May 2018||14 May 2018||15 Jun 2018||USD||—||34c|
|Paid||Quarterly||22 Feb 2018||01 Mar 2018||15 Mar 2018||USD||—||34c|
|Paid||Quarterly||31 Oct 2017||14 Nov 2017||15 Dec 2017||USD||—||34c|
|Paid||Quarterly||03 Aug 2017||11 Aug 2017||15 Sep 2017||USD||—||34c|
|Paid||Quarterly||08 May 2017||16 May 2017||15 Jun 2017||USD||—||34c|
|Paid||Quarterly||23 Feb 2017||01 Mar 2017||15 Mar 2017||USD||—||34c|
|Paid||Quarterly||27 Oct 2016||10 Nov 2016||15 Dec 2016||USD||—||34c|
|Paid||Quarterly||28 Jul 2016||11 Aug 2016||15 Sep 2016||USD||—||34c|
|Paid||Quarterly||02 May 2016||12 May 2016||15 Jun 2016||USD||—||34c|
|Paid||Quarterly||25 Feb 2016||02 Mar 2016||15 Mar 2016||USD||—||34c|
|Paid||Quarterly||29 Oct 2015||10 Nov 2015||14 Dec 2015||USD||—||34c|
|Paid||Quarterly||30 Jul 2015||12 Aug 2015||14 Sep 2015||USD||—||34c|
|Paid||Quarterly||04 May 2015||12 May 2015||15 Jun 2015||USD||—||34c|
|Paid||Quarterly||20 Feb 2015||27 Feb 2015||16 Mar 2015||USD||—||34c|
|Paid||Quarterly||29 Oct 2014||12 Nov 2014||15 Dec 2014||USD||—||34c|
|Paid||Quarterly||30 Jul 2014||13 Aug 2014||15 Sep 2014||USD||—||34c|
|Paid||Quarterly||05 May 2014||13 May 2014||16 Jun 2014||USD||—||34c|
|Paid||Quarterly||21 Feb 2014||28 Feb 2014||14 Mar 2014||USD||—||34c|
|Paid||Quarterly||30 Oct 2013||13 Nov 2013||13 Dec 2013||USD||—||34c|
|Paid||Quarterly||31 Jul 2013||13 Aug 2013||13 Sep 2013||USD||—||34c|
|Paid||Quarterly||03 May 2013||13 May 2013||14 Jun 2013||USD||—||34c|
|Paid||Quarterly||21 Feb 2013||01 Mar 2013||15 Mar 2013||USD||—||34c|
|Paid||Quarterly||31 Oct 2012||13 Nov 2012||14 Dec 2012||USD||—||34c|
|Paid||Quarterly||–||13 Aug 2012||14 Sep 2012||USD||—||34c|
|Paid||Quarterly||–||11 May 2012||15 Jun 2012||USD||—||34c|
|Paid||Quarterly||–||01 Mar 2012||16 Mar 2012||USD||—||34c|
|2022||Sign Up Required|
|2023||Sign Up Required|
|2024||Sign Up Required|
|2025||Sign Up Required|
|2026||Sign Up Required|
Teleflex Incorporated Optimized Dividend Chart
About Teleflex Incorporated
Teleflex Incorporated, incorporated on June 25, 1943, is a provider of medical technology products. The Company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer and Development Services (OEM). As of December 31, 2016, the Company manufactured its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States.
The Company's all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment, which are provided to hospitals and other alternative channels of care. It also includes its Latin American business. Its respiratory products are used in a range of care settings. The products include oxygen therapy products, aerosol therapy products, spirometry products, and ventilation management products. The Company offers Hudson RCI brand. The Company's specialty product line of urology products provide bladder management. The product portfolio consists of a range of catheters, including Foley, intermittent, external and suprapubic; urine collectors; catheterization accessories, and products for operative endourology marketed under the Rusch brand name.
The Company's products in cardiac care product portfolio include diagnostic and intra-aortic balloon catheters and capital equipment. Its diagnostic catheters include thermodilution and wedge pressure catheters; specialized catheters used during the x-ray examination of blood vessels, such as Berman and Reverse Berman catheters; therapeutic delivery catheters, such as temporary pacing catheters; sheaths for femoral and trans-radial aortic access used in diagnostic and therapeutic procedures, and intra-aortic balloon (IAB), catheters. Capital equipment includes its intra-aortic balloon pump (IABP) consoles. The Company markets its cardiac care products under the Arrow brand name.
Vascular North America
The Company's Vascular North America segment consists of its North American vascular and interventional access businesses, which offers products that facilitate a range of critical care therapies and other applications. The vascular access products primarily consist of its Arrow branded catheters and related devices, including catheter positioning systems that are used in a range of procedures, including the administration of intravenous medications and other therapies, the measurement of blood pressure and the withdrawal of blood samples through a single puncture site.
The vascular access product portfolio principally consists of the products, including Arrow Central Venous Catheters (CVCs), Arrow EZ-IO Intraosseous Vascular Access System, Arrow Peripherally Inserted Central Catheters (PICCs), Arrow Jugular Axillo-subclavian Central Catheters (JACCs), Arrow Midline Catheters (Midlines), Arrow Catheter Tip Positioning Systems, Arrow Arterial Catheterization Sets, Arrow Multi-Lumen Access Catheters (MAC) and Arrow Percutaneous Sheath Introducers. The Company's CVCs are treated with solutions based on its ARROWg+ard or ARROWg+ard Blue Plus antimicrobial technology, which has been shown to reduce the risk of catheter related bloodstream infection. Its Chlorag+ard technology, available on its PICCs, JACCs and Midlines, provides antimicrobial and antithrombogenic protection on inner and outer catheter surfaces, as well as the fluid pathway of the catheter. Chlorag+ard technology is effective in reducing microbial colonization and thrombus accumulation on catheter surfaces.
The Company also offers various vascular access catheters in Maximal Barrier Precautions trays, which are designed to assist healthcare providers in complying with clinical guidelines for reducing catheter-related bloodstream infections. These trays are available for CVCs, PICCs and multi access catheters and include a full body drape, coated or non-coated catheters and other accessories. In addition, its ErgoPACK system offers clinicians a range of tray configurations with components packaged in the tray. The Company's interventional access products are used in a range of applications, including dialysis, oncology and critical care therapies. Its interventional access portfolio also includes several Arrow branded products, such as diagnostic and drainage kits, embolectomy balloons, and reinforced percutaneous sheath introducers. Its interventional access products include Arrow OnControl Powered Bone Marrow/Bone Access System, Arrow Trerotola Percutaneous Thrombectomy Device (PTD), Arrow Chronic Hemodialysis Catheters, ARROW-Clark VectorFlow Hemodialysis Catheter, Arrow Acute Hemodialysis Catheters and Arrow Polysite Low Profile Hybrid Ports.
Anesthesia North America
The Company's Anesthesia North America segment consists of its North American airway management and pain management products. The Company's airway management products and related devices consist of various products, including LMA Airways, LMA Atomization and RUSCH Endotracheal Tubes and Laryngoscopes. Its LMA laryngeal masks are used by anesthesiologists and emergency responders to establish an airway to channel anesthesia gas or oxygen to a patient's lungs during surgery or trauma. The LMA Protector Airway, its airway management device, is the first single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber designed specifically to channel high volume, high pressure gastric contents away from the airway. It also integrates its Second Seal technology to isolate the respiratory tract from the digestive tract, reducing the risk of aspiration of gastric contents. The LMA Protector Airway also includes its Cuff Pilot technology, which enables clinicians to confirm that the inserted cuff is properly inflated and to monitor pressure levels.
The Company's LMA atomization portfolio includes products designed to facilitate atomized delivery of certain medications, including LMA MAD Nasal, an intranasal mucosal atomization device that is designed to provide a way to deliver medications approved for intranasal delivery to a patient's blood stream without an intravenous line or needle. The Company's offer a portfolio of products to facilitate and support endotracheal intubation to administer oxygen, and anesthetic gases in multiple settings (surgery, critical care and emergency settings). It also provides a range of products for laryngoscopy, a procedure that is primarily used to obtain a view of the airway to facilitate tracheal intubation during general anesthesia or cardiopulmonary resuscitation (CPR). Among these products is the Rusch DispoLED Laryngoscope Handle and Green Rusch Lite Blade, a single-use system designed to help facilities comply with standards designed to reduce the potential for patient cross-contamination associated with reusable devices during intubation. Its pain management products, which are designed for use in a range of surgical and obstetric procedures, consist of various products, including Arrow Epidural Catheters, Needles and Kits; Arrow Peripheral Nerve Block (PNB) Catheters, Pumps, Needles and Kits; AutoFuser Disposable Pain Pumps and Arrow EZ-IO System.
Surgical North America
The Company's surgical products are designed to provide surgeons with various devices for use in a range of surgical procedures. Its portfolio consists of single-use and reusable products, including Weck Ligation Systems, Weck EFx Fascial Closure Systems and Percutaneous Surgical Systems. Its Weck Ligation Systems features the Weck Ligating Clips and Hem-o-lok Ligating Clips. Its Weck fascial closure systems are used in laparoscopic surgical procedures and are intended to facilitate placement and withdrawal of suture loops to repair port site defects following laparoscopic surgery. Its Weck EFx endo fascial closure system is a port site closure device intended to minimize complications and costs associated with port-site herniation. The MiniLap family of surgical instruments consists of a ThumbGrip option on a 2.3 millimeters (mm) shaft or a pistol design called MiniGrip option on a 2.4mm shaft. Its other branded surgical products include its Weck Vista bladeless access ports, Deknatel sutures and its Pilling and Kmedic surgical instruments.
Europe, the Middle East and Africa
The Company's EMEA segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves two end markets: hospitals and healthcare providers, and home health. The products offered by its EMEA segment are used in acute care settings for a range of diagnostic and therapeutic procedures and in general and specialty surgical applications, such as urology.
The Company's Asia segment, like its EMEA segment, designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The products offered by its Asia segment are used in acute care settings for a range of diagnostic and therapeutic procedures and in general and specialty surgical applications.
Original Equipment Manufacturer and Development Services
The Company's OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. Its OEM division, which includes the TFX OEM and Deknatel OEM brands, provides extrusions, diagnostic and interventional catheters, balloon sheath/dilator sets (introducers) and kits, sutures, performance fibers, and bioresorbable resins and fibers. The Company offers a portfolio of integrated capabilities, including engineering, material selection, regulatory affairs, prototyping, testing and validation, manufacturing, assembly and packing.
The Company competes with C. R. Bard, Inc., Medtronic plc, and Becton, Dickinson and Company.
- Pharmaceuticals & Biotechnology
- United States
- Share Price
- $287.30 (yesterday's closing price)
- Shares in Issue
- 46 million
- Market Cap
- Market Indices
- S&P 500